Insight Molecular Diagnostics Inc (IMDX)

$3.45 -0.21 (-5.74%)
Market Cap 104.67M
Revenue (ttm) 1.88M
Net Income (ttm) -60.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,226.60%
Debt to Equity Ratio 0.00
Volume 140,200
Avg Vol 83,880
Day's Range N/A - N/A
Shares Out 28.60M
Stochastic %K 53%
Beta 0.97
Analysts Sell
Price Target $5.42
Latest News on IMDX
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 23, 2025, 4:05 PM EDT - 1 day ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Jun 17, 2025, 7:00 AM EDT - 7 days ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 19, 2025, 4:05 PM EDT - 5 weeks ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 11:32 PM EDT - 6 weeks ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025, 4:05 PM EDT - 6 weeks ago

Oncocyte Reports Q1 2025 Results and Business Progress

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025, 4:10 PM EDT - 6 weeks ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 30, 2025, 8:30 AM EDT - 7 weeks ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Apr 29, 2025, 8:30 AM EDT - 2 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 6:53 PM EDT - 3 months ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025, 4:05 PM EDT - 3 months ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025, 8:30 AM EST - 4 months ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 8, 2025, 8:30 AM EST - 5 months ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025, 4:05 PM EST - 6 months ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:52 PM EST - 8 months ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 6, 2024, 4:45 PM EST - 8 months ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024, 4:15 PM EDT - 8 months ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:00 PM EDT - 11 months ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

Oncocyte Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 1:44 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Oncocyte Reports Full Year 2023 Financial Results

Apr 12, 2024, 6:00 AM EDT - 1 year ago

Oncocyte Reports Full Year 2023 Financial Results

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:36 AM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Oncocyte Announces 1-For-20 Reverse Stock Split

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Jun 1, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Oncocyte Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

Oncocyte Reports First Quarter 2023 Financial Results

Oncocyte To Announce First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 2 years ago

Oncocyte To Announce First Quarter 2023 Financial Results

Oncocyte Presents New Data at AACR

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Oncocyte Presents New Data at AACR

Oncocyte Announces Reduction in Force

Apr 12, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Announces Reduction in Force

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Apr 7, 2023, 8:24 AM EDT - 2 years ago

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Apr 3, 2023, 11:40 AM EDT - 2 years ago

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Mar 31, 2023, 5:00 PM EDT - 2 years ago

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Mar 2, 2023, 9:00 AM EST - 2 years ago

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Oncocyte Completes Razor Genomics Transaction

Feb 22, 2023, 8:00 AM EST - 2 years ago

Oncocyte Completes Razor Genomics Transaction

Oncocyte cuts 40% of staff

Dec 16, 2022, 8:19 AM EST - 2 years ago

Oncocyte cuts 40% of staff

Oncocyte Announces Initiatives to Focus Corporate Strategy

Dec 16, 2022, 8:00 AM EST - 2 years ago

Oncocyte Announces Initiatives to Focus Corporate Strategy

Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

Nov 30, 2022, 6:05 PM EST - 2 years ago

Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

Oncocyte Announces Executive Leadership Changes

Nov 30, 2022, 6:00 PM EST - 2 years ago

Oncocyte Announces Executive Leadership Changes

OncoCyte Corporation (OCX) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 9:50 PM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2022 Earnings Call Transcript

Oncocyte Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 4:30 PM EST - 2 years ago

Oncocyte Reports Third Quarter 2022 Financial Results

Oncocyte to Announce Third Quarter 2022 Financial Results

Oct 27, 2022, 4:01 PM EDT - 2 years ago

Oncocyte to Announce Third Quarter 2022 Financial Results

Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference

Aug 31, 2022, 4:01 PM EDT - 3 years ago

Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference

Oncocyte Announces Five-Year VA Contract for DetermaRx

Aug 30, 2022, 4:27 PM EDT - 3 years ago

Oncocyte Announces Five-Year VA Contract for DetermaRx